Highlights of ACC 2024
Cardiology Update
APRIL 9, 2024
STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5).
Let's personalize your content